- Home
- APRE vs PMCB Comparison
APRE vs PMCB Comparison
Compare APRE & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- PMCB
- Stock Information
- Founded
- APRE 2006
- PMCB 1996
- Country
- APRE United States
- PMCB United States
- Employees
- APRE N/A
- PMCB N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APRE Health Care
- PMCB Health Care
- Exchange
- APRE Nasdaq
- PMCB Nasdaq
- Market Cap
- APRE 6.9M
- PMCB 6.6M
- IPO Year
- APRE 2019
- PMCB N/A
- Fundamental
- Price
- APRE $1.16
- PMCB $0.65
- Analyst Decision
- APRE Strong Buy
- PMCB
- Analyst Count
- APRE 1
- PMCB 0
- Target Price
- APRE $20.00
- PMCB N/A
- AVG Volume (30 Days)
- APRE 84.3K
- PMCB 39.6K
- Earning Date
- APRE 11-12-2025
- PMCB 12-12-2025
- Dividend Yield
- APRE N/A
- PMCB N/A
- EPS Growth
- APRE N/A
- PMCB N/A
- EPS
- APRE N/A
- PMCB 0.01
- Revenue
- APRE $488,239.00
- PMCB N/A
- Revenue This Year
- APRE N/A
- PMCB N/A
- Revenue Next Year
- APRE N/A
- PMCB N/A
- P/E Ratio
- APRE N/A
- PMCB $103.27
- Revenue Growth
- APRE N/A
- PMCB N/A
- 52 Week Low
- APRE $1.08
- PMCB $0.63
- 52 Week High
- APRE $5.00
- PMCB $1.90
- Technical
- Relative Strength Index (RSI)
- APRE 37.51
- PMCB 25.41
- Support Level
- APRE $1.08
- PMCB $0.63
- Resistance Level
- APRE $1.28
- PMCB $0.93
- Average True Range (ATR)
- APRE 0.09
- PMCB 0.09
- MACD
- APRE -0.01
- PMCB -0.02
- Stochastic Oscillator
- APRE 30.53
- PMCB 3.33
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.